0.350
0.01 (2.91%)
| Previous Close | 0.340 |
| Open | 0.344 |
| Volume | 585,662 |
| Avg. Volume (3M) | 1,458,719 |
| Market Cap | 20,728,294 |
| Price / Book | 0.460 |
| 52 Weeks Range | |
| Earnings Date | 2 May 2025 - 5 May 2025 |
| Diluted EPS (TTM) | -0.810 |
| Total Debt/Equity (MRQ) | 66.87% |
| Current Ratio (MRQ) | 19.40 |
| Operating Cash Flow (TTM) | -39.50 M |
| Levered Free Cash Flow (TTM) | -22.38 M |
| Return on Assets (TTM) | -29.86% |
| Return on Equity (TTM) | -78.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Elevation Oncology, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 0.0 |
| Average | -0.17 |
|
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.36% |
| % Held by Institutions | 57.31% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |